From the Journals

Adding vasopressin in distributive shock may cut AF risk


 

FROM JAMA


Dr. McIntyre and his colleagues included 23 trials that had enrolled a total of 3,088 patients with distributive shock, a condition in which widespread vasodilation lowers vascular resistances and mean arterial pressure. Sepsis is its most common cause. The current study is one of the first to directly compare the combination of vasopressin and catecholamine to catecholamines alone, which is the current standard of care, the investigators wrote.

They found that the administration of vasopressin was associated with a significant 23% reduction in risk of atrial fibrillation.

“The absolute effect is that 68 fewer people per 1,000 patients will experience atrial fibrillation when vasopressin is added to catecholaminergic vasopressors,” Dr. McIntyre and his coauthors said of the results.

The atrial fibrillation finding was judged to be high-quality evidence, they said, noting that two separate sensitivity analyses confirmed the benefit.

Pages

Recommended Reading

Late-Breaking Science preview: Sunday, Nov. 12
MDedge Hematology and Oncology
Direct oral anticoagulants okay during AF device placement
MDedge Hematology and Oncology
VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
MDedge Hematology and Oncology
Surgical LAA occlusion tops anticoagulation for AF thromboprotection
MDedge Hematology and Oncology
LAA occlusion boosts anticoagulants’ protection
MDedge Hematology and Oncology
Beware of polypharmacy in patients taking warfarin
MDedge Hematology and Oncology
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
MDedge Hematology and Oncology
MDedge Daily News: Time to let more pregnant women into drug trials?
MDedge Hematology and Oncology
MDedge Daily News: Which diabetes drug boosts survival best?
MDedge Hematology and Oncology
First reversal agent for apixaban and rivaroxaban gets fast-track approval
MDedge Hematology and Oncology